vTv Therapeutics (NASDAQ:VTVT) Share Price Passes Above 50 Day Moving Average of $18.21

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $18.21 and traded as high as $24.96. vTv Therapeutics shares last traded at $24.74, with a volume of 3,423 shares trading hands.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of vTv Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, March 14th.

vTv Therapeutics Price Performance

The stock's fifty day simple moving average is $18.48 and its 200-day simple moving average is $14.49. The company has a market capitalization of $72.36 million, a P/E ratio of -2.39 and a beta of 0.56.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last released its quarterly earnings results on Wednesday, March 13th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On vTv Therapeutics

Several hedge funds have recently made changes to their positions in VTVT. Pathstone Family Office LLC bought a new stake in shares of vTv Therapeutics in the third quarter valued at about $116,000. State Street Corp lifted its stake in shares of vTv Therapeutics by 268.7% in the second quarter. State Street Corp now owns 206,145 shares of the biotechnology company's stock valued at $155,000 after buying an additional 150,228 shares during the period. Prudential Financial Inc. bought a new stake in shares of vTv Therapeutics in the second quarter valued at about $30,000. Finally, Millennium Management LLC lifted its stake in shares of vTv Therapeutics by 12.0% in the second quarter. Millennium Management LLC now owns 138,683 shares of the biotechnology company's stock valued at $104,000 after buying an additional 14,845 shares during the period. Institutional investors own 17.51% of the company's stock.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes that is in Phase III clinical trial; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases, psoriasis, COPD, and Atopic Dermatitis that is in Phase III clinical trial.